Dr. Vijay Yabannavar Ph.D. serves as Executive Vice President, Manufacturing and Technical Operations of the Company. Dr. Yabannavar has served as our Executive Vice President, Manufacturing and Technical Operations, since July 2019. Previously, Dr. Yabannavar served as vice president of global technical operations (vaccines, biologics and sterile operations) at Merck from 2015 until June 2019. Prior to 2015, he was senior vice president of manufacturing & technical development at Emergent BioSolutions, and the site head of Emergent’s Baltimore manufacturing facility with a biodefense focus. From 2007 to 2010, Dr. Yabannavar was vice president of process development and manufacturing at Trubion Pharmaceuticals. Prior to that, he was the head of technical research and development for Novartis Pharmaceuticals. Dr. Yabannavar also held similar technical product and process development roles at Chiron Corporation and Schering-Plough Corporation. He has served as a member of the Advisory Board for the Chemical Engineering and Materials Science Department at the University of California, Davis. Dr. Yabannavar obtained his Ph.D. in chemical engineering from the Massachusetts Institute of Technology and his B. Tech. in chemical engineering from the Indian Institute of Technology Bombay.
Vijay Yabannavar is 59, he's been the Executive Vice President und Manufacturing and Technical Operations of Gritstone Bio Inc since 2019. There are 3 older and 16 younger executives at Gritstone Bio Inc. The oldest executive at Gritstone Bio Inc is Alan C. Mendelson J.D., 71, who is the Sec..
Vijay's mailing address filed with the SEC is C/O GRITSTONE BIO, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE, CA, 94608.
Over the last 6 years, insiders at Gritstone Bio Inc have traded over $277,077 worth of Gritstone Bio Inc stock and bought 2,026,375 units worth $15,022,790 . The most active insiders traders include Group, Llc Green Jeremy Red..., Peter Svennilson und Thomas Woiwode. On average, Gritstone Bio Inc executives and independent directors trade stock every 103 days with the average trade being worth of $54,654. The most recent stock trade was executed by Andrew R Allen on 15 May 2024, trading 24,263 units of GRTS stock currently worth $18,197.
gritstone oncology is a cancer immunotherapy company developing next-generation personalized cancer therapeutics. gritstone brings together distinguished scientific founders, an experienced and diverse management team, a seasoned and successful board of directors, and very deep financial backing to tackle fundamental challenges at the intersection of cancer biology, immunology, and immunotherapy design. the company’s initial goal is to identify and deploy therapeutic neo-antigens from individual patients’ tumors to develop novel treatments for lung cancer. gritstone oncology is headquartered in the san francisco bay area with certain key functions located in cambridge, ma. gritstone oncology launched in october 2015 with a series a financing of $102 million.
Gritstone Bio Inc executives and other stock owners filed with the SEC include: